Research Library — Schedule II & RFK | Reta Compare
39 research articles in Schedule II & RFK. Page 1 of 2.
Articles
- Overview: Peptides and the Schedule II Debate
- RFK Jr. on Peptides: Public Statements and Interviews
- HHS Peptide Policy Review Under RFK Jr.
- DEA Scheduling of Peptide-Category Substances
- The 'Coming Off Schedule II' Narrative for Peptides
- BPC-157 and Regulatory Status in 2026
- TB-500 and the 2026 Scheduling Debate
- CJC-1295 and Ipamorelin in 2026 Policy Discussions
- RFK Jr.'s HHS Staff on Peptide Policy
- Federal Research Peptide Policy in 2026
- Peptide Industry Response to RFK Jr.'s Agenda
- Public Comments to HHS Peptide Policy Review
- Peptide Legislation in the 119th Congress
- RFK Jr. on the Joe Rogan Experience: Peptide Discussion
- State-Level Peptide Legislation in 2026
- RFK Jr. on FDA Reform and Peptides
- HHS Memorandum on Peptide Research Access
- NIH Budget Requests for Peptide Science 2026
- How State Boards of Pharmacy Are Responding to RFK Jr.'s Agenda
- Peptide Scientific Advisory Committees Under the New HHS
- The Peptide Industry Trade Associations and 2026 Advocacy
- Consumer Advocacy Groups on Peptide Policy Reform
- Academic Researchers' Letters to HHS on Peptide Regulation
- RFK Jr. Interviews with Peptide Researchers: Key Themes
- Peptide Congressional Caucus Activity in 2026